|
|||||
|
|
Impact of PCSK9 inhibitors on plasma lipoprotein(a) concentrations with or without a background of niacin therapy |
|
| Authors: | Bruce A. Warden Jessica Minnier Gerald F. Watts Sergio Fazio Michael D. Shapiro |
| Affiliation: | 1. Center for Preventive Cardiology, Knight Cardiovascular Institute, Oregon Health & Science University, Portland, OR, USA;2. Department of Cardiology, The Lipid Disorders Clinic, Royal Perth Hospital, School of Medicine, University of Western Australia, Perth, WA, Australia |
| Abstract: | |
| Keywords: | Corresponding author. Center for Preventive Cardiology, Knight Cardiovascular Institute, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA. Lipoprotein(a) Proprotein convertase subtilisin/kexin type 9 inhibitors Niacin Atherosclerotic cardiovascular disease Pharmacotherapy |
| 本文献已被 ScienceDirect 等数据库收录！ | |